SS Innovations International, Inc. (NASDAQ: SSII) announced significant growth in the utilization and global reach of its SSi Mantra surgical robotic system, with cumulative procedures surging 79% to 14,103 as of Sept. 8, 2026, up from 7,885 at the end of 2025. The installed base of SSi Mantra systems climbed 42% to 238 units from 168, now spanning 12 countries. These figures underscore the company's accelerating momentum in the surgical robotics market and its potential to challenge established players by offering a more affordable and accessible alternative.
The expansion is not just about numbers; it reflects a broadening clinical acceptance. Approximately 1,500 physicians have been trained on the SSi Mantra platform, and the system has been used for more than 170 types of surgical procedures. Recent international milestones include the launch of robotic cardiac surgery in Colombia, the installation of the first SSi Mantra in Sri Lanka, and the first telesurgery within the Philippines. These developments highlight the system's versatility and its ability to facilitate advanced surgical care in diverse healthcare settings.
SS Innovations also reported 258 cumulative pediatric robotic surgeries and 188 robotic telesurgeries as of Aug. 31, including a record-setting telesurgery conducted over more than 13,600 miles between Colombia and India. In August, five SSi Mantra systems were used to complete 50 robotic general surgery procedures in a single day in India, demonstrating the platform's efficiency and reliability in high-volume environments. Such achievements are critical as they showcase the system's capacity to handle complex, high-demand surgical workflows.
Looking ahead, the company expects the U.S. Food and Drug Administration to complete its review of the SSi Mantra 510(k) premarket notification by the end of the first quarter of 2027. Additionally, SS Innovations believes European Union CE marking certification can be obtained by year-end 2026. These regulatory milestones are pivotal; FDA clearance and CE marking would open the door to the world's largest medical device markets, significantly expanding the company's addressable market and revenue potential. For investors, these approvals would validate the technology's safety and efficacy, potentially accelerating adoption among U.S. and European hospitals.
The broader implications of SS Innovations' growth extend beyond the company itself. By making robotic surgery more affordable and accessible, SS Innovations aims to democratize advanced surgical care, particularly in emerging markets where such technology has been historically out of reach. The company's vision, as stated in its report, is to make the benefits of robotic surgery available to a larger segment of the global population. This could lead to improved patient outcomes and increased access to minimally invasive procedures worldwide.
For more details, the full report is available at https://ibn.fm/DJILj. Investors can also find the latest news and updates in the company's newsroom at https://ibn.fm/SSII. As SS Innovations continues to expand its global footprint, its progress will be closely watched by industry analysts and investors alike, given the potential to disrupt the surgical robotics landscape.
